Literature DB >> 17188385

Inhibitory effects of an orexin-2 receptor antagonist on orexin A- and stress-induced ACTH responses in conscious rats.

Hyukki Chang1, Tsuyoshi Saito, Nao Ohiwa, Masaru Tateoka, Custer C Deocaris, Takahiko Fujikawa, Hideaki Soya.   

Abstract

Orexins, recognized for their diverse functions in sleep/wakefulness/arousal and appetite regulation, may play provocative roles in stress response. Although the PVN of the hypothalamus expresses an abundance of orexin-2 receptor (OX-2R), the involvement of OX-2R in regulating ACTH response to stress remains unclear. To address this, we examined effects of a selective antagonist to OX-2R (N-{(1S)-1-[6,7-dimethoxy-3,4-dihydro-2(1H)-isoquinolinyl]carbonyl}-2,2-dimethylpropyl)-N-{4-pyridinylmethyl}amine upon plasma ACTH concentrations after administration of orexin A and swimming stress. Increases in ACTH levels with orexin A or swimming stress were attenuated with prior administration of an OX-2R antagonist. These results suggest that swimming stress facilitates ACTH release, at least in part via activation of OX-2R.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17188385     DOI: 10.1016/j.neures.2006.11.009

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  33 in total

1.  Orexins in the paraventricular nucleus of the thalamus mediate anxiety-like responses in rats.

Authors:  Yonghui Li; Sa Li; Chuguang Wei; Huiying Wang; Nan Sui; Gilbert J Kirouac
Journal:  Psychopharmacology (Berl)       Date:  2010-07-20       Impact factor: 4.530

2.  Differential effects of the hypocretin 1 receptor antagonist SB 334867 on high-fat food self-administration and reinstatement of food seeking in rats.

Authors:  S G Nair; S A Golden; Y Shaham
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

Review 3.  The hypocretins/orexins: integrators of multiple physiological functions.

Authors:  Jingcheng Li; Zhian Hu; Luis de Lecea
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 4.  A Decade of Orexin/Hypocretin and Addiction: Where Are We Now?

Authors:  Morgan H James; Stephen V Mahler; David E Moorman; Gary Aston-Jones
Journal:  Curr Top Behav Neurosci       Date:  2017

Review 5.  Orexin, stress, and anxiety/panic states.

Authors:  Philip L Johnson; Andrei Molosh; Stephanie D Fitz; William A Truitt; Anantha Shekhar
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

6.  A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects.

Authors:  Pascal Bonaventure; Sujin Yun; Philip L Johnson; Anantha Shekhar; Stephanie D Fitz; Brock T Shireman; Terry P Lebold; Diane Nepomuceno; Brian Lord; Michelle Wennerholm; Jonathan Shelton; Nicholas Carruthers; Timothy Lovenberg; Christine Dugovic
Journal:  J Pharmacol Exp Ther       Date:  2015-01-12       Impact factor: 4.030

7.  Stress induces analgesia via orexin 1 receptor-initiated endocannabinoid/CB1 signaling in the mouse periaqueductal gray.

Authors:  Hsin-Jung Lee; Lu-Yang Chang; Yu-Cheng Ho; Shu-Fang Teng; Ling-Ling Hwang; Ken Mackie; Lih-Chu Chiou
Journal:  Neuropharmacology       Date:  2016-02-18       Impact factor: 5.250

8.  Comparison of Lactate Threshold, Glucose, and Insulin Levels Between OLETF and LETO Rats After All-Out Exercise.

Authors:  Hyukki Chang; Jae-Young Park; Min-Hwa Suk; Lee Ho-Jun; Hyun-Joo Kang; Kyung-Mook Choi; Wook Song
Journal:  J Sports Sci Med       Date:  2009-09-01       Impact factor: 2.988

Review 9.  The neuropharmacology of relapse to food seeking: methodology, main findings, and comparison with relapse to drug seeking.

Authors:  Sunila G Nair; Tristan Adams-Deutsch; David H Epstein; Yavin Shaham
Journal:  Prog Neurobiol       Date:  2009-06-02       Impact factor: 11.685

10.  Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor.

Authors:  P Malherbe; E Borroni; L Gobbi; H Knust; M Nettekoven; E Pinard; O Roche; M Rogers-Evans; J G Wettstein; J-L Moreau
Journal:  Br J Pharmacol       Date:  2009-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.